Orexo’s comprehensive Business Compliance and Ethics Code ensures that sustainability permeates business operations. The sustainability agenda is based on the company’s core values of customer focus, engagement, flexibility and simplicity, and the work on sustainability focuses on the entire value chain.

Focus on the entire value chain

Orexo’s sustainability work includes the entire value chain, both internal work and collaboration with external parties. Orexo has therefore established both an internal Code of Conduct and a special Supplier Code of Conduct in order to make clear the standard that is to permeate the business.

Product development

Orexo focuses on developing new products on the basis of its proprietary drug delivery technology. Evaluation of product risks and safety aspects is an integral part of the product development process. The evaluation covers all phases of the product’s life cycle. Orexo conducts clinical studies in collaboration with external experts. Studies are designed in consultation with these partners, and risk and benefit assessments are conducted. The studies require regulatory approval, and regulations and ethical issues must be taken into account internationally and in the various countries where a study is conducted. Since the studies are based on well-known compounds, the risk level is generally lower relative to clinical tests of new molecules.

Product supply and outsourced activities

Orexo’s Supplier Code of Conduct serves as a guide in the procurement of goods and services and informs suppliers of what Orexo expects. The Code covers business ethics, labor conditions, health and safety, product safety, supply chain integrity and the management system. The Code is applied in the evaluation of new potential suppliers and in collaboration with existing suppliers. Risk is assessed, as well as how Orexo can impact the supplier’s work regarding environmental management and health and safety. Should a supplier not meet Orexo’s requirements, the company will initiate a dialog to achieve improvements.

Orexo’s Supplier Code of Conduct serves as a guide in the procurement of goods and services


Orexo’s main market today is the American market for treatment of opioid dependence. A large increase in the number of prescription drugs and an increased range of illegal drugs has made more and more Americans dependent. Overdose mortality tripled during the period 1999– 2014 and is today one of the most common causes of death.1 Socially exposed groups in society are particularly impacted, especially women.2 Being dependent on opioids impacts not only the individual person but also many people in the immediate environment. In the USA the disease affects entire families and children are hardest hit.

Orexo’s main product Zubsolv® is an effective drug for people suffering from opioid dependence. The drug should be used as part of a complete treatment plan, including counseling and psychosocial support.

Society economy

The extensive dependence on opioids in the USA involves a considerable burden for society from an economic point of view. In addition to loss of life and lower quality of life, large costs are associated with lower productivity and a lack of resources, as well as increased costs related to healthcare and prison care. The American National Institute of Drug Abuse estimates that the total cost to society related to dependence on illegal drugs, including opioid dependence, amounts to USD 193 billion per year.3

Orexo’s presence in the market means that, together with several other players, the company contributes to reducing the economic burden that opioid dependence involves for American society. A concrete example is when Zubsolv® was selected in 2016 by the state of Maryland as the only recommended buprenorphine/naloxone drug on their FFS Medicaid list. The introduction of Zubsolv has, amongst other things, reduced the smuggling of similar drugs into prisons, which has had a positive impact on costs for society.

1 https://www.cdc.gov/mmwr/volumes/65/wr/pdfs/mm655051e1.pdf
2 World Drug Report 2016